Pharma Letter -- The European Union’s Innovative Medicines Initiative (IMI), Europe’s largest public-private partnership in the biopharmaceutical sector, yesterday launched its second wave of research projects. With a total budget of 172 million euros ($240.8 million), the eight new projects will aim to develop new treatments for cancer, rheumatoid arthritis and infectious diseases.
